Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility.

Polymorphisms in the vascular endothelial growth factor (VEGF) gene may contribute to osteosarcoma risk, but the results of previous studies have been inconsistent and inconclusive. We conducted a meta-analysis to assess this association more accurately. Relevant studies were collected systemically from three online English databases. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations of three VEGF gene polymorphisms (+936C/T, -634 G/C, +1612 G/A) with osteosarcoma risk. Seven case-control studies involving 1,350 cases and 1,706 controls were selected for the meta-analysis. The pooled OR indicated that the VEGF +936C/T polymorphism was associated with increased risk of osteosarcoma in a Chinese population (T vs. C: OR = 1.26, 95% CI = 1.12-1.42, P < 0.01; TT vs. CC: OR = 1.70, 95% CI = 1.29-2.24, P < 0.01; CT + TT vs. CC: OR = 1.23, 95% CI = 1.06-1.44, P < 0.01; TT vs. CC + CT: OR = 1.61, 95% CI = 1.23-2.10, P < 0.01). A significant association was also found between the -634 G/C polymorphism and osteosarcoma risk (C vs. G: OR = 0.81, 95% CI = 0.69-0.96, P = 0.01; CC vs. GG: OR = 0.66, 95% CI = 0.48-0.90, P < 0.01; GC + CC vs. GG: OR = 0.80, 95% CI = 0.67-0.96, P = 0.02; CC vs. GG + GC: OR = 0.72, 95% CI = 0.60-0.86, P < 0.01). In sum, our meta-analysis suggests VEGF polymorphisms are associated with osteosarcoma susceptibility in the Chinese population. However, further studies that include different ethnicities and larger populations are needed.